Earnings ·
Apyx Medical reports Q3 revenue of $14.0M and reaffirms FY2026 guidance
APYXApyx Medical Corp
Apyx Medical reported third-quarter 2026 total revenue of $14.0 million, a 9% increase from the prior year period, driven by a 17% rise in Surgical Aesthetics sales to $13.0 million. The company initiated the full commercial launch of the power liposuction handpiece for its AYON system and published clinical data supporting Renuvion's effects on skin quality. Net loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, compared with a $2.0 million loss in the prior year, while Adjusted EBITDA turned positive at $0.4 million. Management reaffirmed full-year 2026 revenue guidance of $59.0 million to $60.0 million and lowered operating expense expectations to $41.0 million–$42.5 million. Apyx Medical Corporation is a surgical aesthetics company that markets Renuvion, J-Plasma, and the AYON Body Contouring System.